Management of mantle cell lymphoma in the elderly patient
Open Access
- 1 September 2013
- journal article
- review article
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. 8, 1229-36
Abstract
Peer reviewed article authored by (Doorduijn JK, Kluin-Nelemans HC). Read article or submit your manuscript for publishing.Keywords
This publication has 57 references indexed in Scilit:
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous TransplantationJournal of Clinical Oncology, 2013
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'AdulteBlood, 2013
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaBlood, 2011
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation studyLeukemia & Lymphoma, 2009
- Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupBlood, 2008
- A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomaAnnals of Oncology, 2007
- Leukemic involvement is a common feature in mantle cell lymphomaCancer, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007